Skip to main content

Table 2 Clinical and demographic characteristics of included patients

From: Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa

  Included patients (n = 91)
Age, years* 67 (24–88)
Male sex, n (%) 66 (72.5)
APACHE II* 11 (2–28)
Co-morbidities, n (%):
 Malignancy 14 (15.4)
 Cardiovascular 26 (28.6)
 Pulmonary 33 (36.3)
 Diabetes Mellitus 21 (23.1)
 Urogenitala 14 (15.4)
 Hepatic 8 (8.8)
 Haematologicalb 12 (13.2)
 Neurologicalc 18 (19.2)
Charlson score* 4 (0–10)
McCabe score** 1.48 ± 0.64
Patients with CKD1 at baseline 19 (20.9)
Type of infection, n (%):
 Pneumonia 24 (24.6)
 Urinary tract infection 22 (24.2)
 Skin and soft tissue infection 11 (12.1)
 Organ space surgical site infection 10 (11)
 Bacteremia 6 (6.6)
 Other 18 (19.8)
 Hospital-acquired infection, n (%) 86 (94.5)
Department of hospitalization:
 Medical 44 (48.2)
 Surgical 32 (35.2)
 ICU2 15 (16.2)
Admission diagnosis category:
 Infection 26 (28.6)
 Other-medical 35 (38.5)
 Other-surgical 30 (33)
CMS3 daily dose (millions of IU4)** 5.45 ± 2.21
CMS3 total dose (millions of IU4)** 108.36 ± 96.41
CMS3 duration of treatment, days** 20.18 ± 16.01
Inhaled CMS3, n (%) 14 (15.4)
Combined antimicrobial therapy, n (%) 46 (50.5)
Css 5 (mg/L)** 1.67 ± 1.42
Css 5 > 1.28 (mg/L), n (%) 46 (50.5)
Css 5/MIC6** 3.43 ± 2.91
AKI7 prior to CMS3 treatment, n (%) 12 (13.2)
Patients with AKI at day 7, n (%)
 R (Risk) 19 (20.9)
 I (Injury) 9 (9.9)
 F (Failure) 2 (2.2)
Patients with AKI7 at the EOT8, n (%)
 R (Risk) 12 (13.2)
 I (Injury) 27 (27.7)
 F (Failure) 10 (11)
Clinical response, n (%) 72 (79.1)
30-Day all-cause mortality, n (%) 28 (30)
Hospital length-of-stay (days)* 67 ± 53.97
  1. 1 CKD chronic kidney disease, 2 ICU intensive cure unit, 3 CMS colistin methanesulphonate, 4 IU international units, 5 C ss colistin plasma concentration at steady-state, 6 MIC minimal inhibitory concentration, 7 AKI acute kidney injury, 8 EOT end of treatment
  2. *median (range)
  3. **mean ± SD
  4. aAmong urogenital co-morbidities were, renal disease, kidney stones and obstructive uropathy
  5. bAmong haematological co-morbidities were haemopoietic and lymphoreticular malignances
  6. cAmong neurological co-morbidities were Alzheimer’s disease, stroke, miastenia gravis, sclerosis and any kind of dementia